SHIP1 and its role for innate immune regulation-Novel targets for immunotherapy.

Autor: Yeoh WJ; Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland., Krebs P; Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
Jazyk: angličtina
Zdroj: European journal of immunology [Eur J Immunol] 2023 Dec; Vol. 53 (12), pp. e2350446. Date of Electronic Publication: 2023 Oct 27.
DOI: 10.1002/eji.202350446
Abstrakt: Phosphoinositide-3-kinase/AKT (PI3K/AKT) signaling plays key roles in the regulation of cellular activity in both health and disease. In immune cells, this PI3K/AKT pathway is critically regulated by the phosphoinositide phosphatase SHIP1, which has been reported to modulate the function of most immune subsets. In this review, we summarize our current knowledge of SHIP1 with a focus on innate immune cells, where we reflect on the most pertinent aspects described in the current literature. We also present several small-molecule agonists and antagonists of SHIP1 developed over the last two decades, which have led to improved outcomes in several preclinical models of disease. We outline these promising findings and put them in relation to human diseases with unmet medical needs, where we discuss the most attractive targets for immune therapies based on SHIP1 modulation.
(© 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.)
Databáze: MEDLINE
Externí odkaz: